标题
Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
作者
关键词
-
出版物
Frontiers in Immunology
Volume 14, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-07-24
DOI
10.3389/fimmu.2023.1199145
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Protection of cell therapeutics from antibody-mediated killing by CD64 overexpression
- (2023) Alessia Gravina et al. NATURE BIOTECHNOLOGY
- The emerging roles of γδ T cells in cancer immunotherapy
- (2023) Sofia Mensurado et al. Nature Reviews Clinical Oncology
- Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
- (2023) Sham Mailankody et al. NATURE MEDICINE
- IL-33 promotes double negative T cell survival via the NF-κB pathway
- (2023) Xiaojing Sun et al. Cell Death & Disease
- Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes
- (2023) Alex Look et al. Frontiers in Immunology
- Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non–Gene-edited Allogeneic CAR T-Cell Therapy
- (2022) Alexandre Michaux et al. JOURNAL OF IMMUNOTHERAPY
- CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer
- (2022) Zhiheng Wu et al. Frontiers in Immunology
- Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models
- (2022) Kevin P Nishimoto et al. Clinical & Translational Immunology
- 3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells
- (2022) Zhiqiang Wang et al. Cell Stem Cell
- Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
- (2022) Alexander Dimitri et al. Molecular Cancer
- FDA approves second BCMA-targeted CAR-T cell therapy
- (2022) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT
- (2022) Hana Andrlová et al. Science Translational Medicine
- Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
- (2022) Mayumi Sugita et al. Nature Communications
- Next-Generation CAR T-cell Therapies
- (2022) Regina M. Young et al. Cancer Discovery
- Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities
- (2022) Daniel Vasic et al. Science Immunology
- EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity
- (2022) Ran Jing et al. Cell Stem Cell
- Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage
- (2022) Alessio David Nahmad et al. NATURE BIOTECHNOLOGY
- Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
- (2022) Sumin Jo et al. Nature Communications
- Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy
- (2022) Mikail Dogan et al. JOURNAL OF IMMUNOLOGY
- The journey of CAR-T therapy in hematological malignancies
- (2022) Junru Lu et al. Molecular Cancer
- Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia
- (2022) Giorgio Ottaviano et al. Science Translational Medicine
- Target tumor microenvironment by innate T cells
- (2022) Yan-Ruide Li et al. Frontiers in Immunology
- UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
- (2022) Reuben Benjamin et al. Lancet Haematology
- Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
- (2022) Diego Sánchez Martínez et al. Journal for ImmunoTherapy of Cancer
- Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
- (2022) Amitkumar Mehta et al. BLOOD
- Mucosal-associated invariant T cells for cancer immunotherapy
- (2022) Yan-Ruide Li et al. MOLECULAR THERAPY
- The SIRPα–CD47 immune checkpoint in NK cells
- (2021) Tobias Deuse et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy
- (2021) Shoichi Iriguchi et al. Nature Communications
- CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia
- (2021) Yongxian Hu et al. CLINICAL CANCER RESEARCH
- Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?
- (2021) Amanda M. DiNofia et al. Nature Reviews Clinical Oncology
- Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection
- (2021) Tiphaine Parrot et al. JCI Insight
- Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing
- (2021) Mitchell L. Leibowitz et al. NATURE GENETICS
- Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells
- (2021) Bo Wang et al. Nature Biomedical Engineering
- Mutant B2M‐HLA‐E and B2M‐HLA‐G fusion proteins protects universal chimeric antigen receptor‐modified T cells from allogeneic NK cell‐mediated lysis
- (2021) Yelei Guo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- DL4-μbeads induce T cell lineage differentiation from stem cells in a stromal cell-free system
- (2021) Ashton C. Trotman-Grant et al. Nature Communications
- Immunicy-1: Targeting BCMA with Cyad-211 to Establish Proof of Concept of an shRNA-Based Allogeneic CAR T Cell Therapy Platform
- (2021) Ahmad-Samer Al-Homsi et al. BLOOD
- Allogeneic NKT Cells Expressing a CD19-Specific CAR in Patients with Relapsed or Refractory B-Cell Malignancies: An Interim Analysis
- (2021) Carlos A. Ramos et al. BLOOD
- A systematic genome-wide mapping of oncogenic mutation selection during CRISPR-Cas9 genome editing
- (2021) Sanju Sinha et al. Nature Communications
- Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
- (2021) Amani Makkouk et al. Journal for ImmunoTherapy of Cancer
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- CYAD-101: An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy.
- (2020) Hans Prenen et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy
- (2020) Yuki Kagoya et al. Cancer Immunology Research
- Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR
- (2020) Dana Stenger et al. BLOOD
- Cancer immunotherapy with γδ T cells: many paths ahead of us
- (2020) Dieter Kabelitz et al. Cellular & Molecular Immunology
- Engineered off-the-shelf therapeutic T cells resist host immune rejection
- (2020) Feiyan Mo et al. NATURE BIOTECHNOLOGY
- Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
- (2020) Meir Rozenbaum et al. Frontiers in Immunology
- MAIT Cell Development and Functions: the Microbial Connection
- (2020) François Legoux et al. IMMUNITY
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
- (2020) Andras Heczey et al. NATURE MEDICINE
- Eradication of T-ALL cells by CD7 targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management
- (2020) Shiqi Li et al. CLINICAL CANCER RESEARCH
- Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells
- (2019) Amélie Montel-Hagen et al. Cell Stem Cell
- Developing allogeneic double negative T cells as a novel off-the-shelf adoptive cellular therapy for cancer
- (2019) Jong Bok Lee et al. CLINICAL CANCER RESEARCH
- Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15
- (2019) Junlin Yao et al. Journal for ImmunoTherapy of Cancer
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
- (2019) Tobias Deuse et al. NATURE BIOTECHNOLOGY
- Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade
- (2019) Linan Fang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Manufacturing chimeric antigen receptor T cells: issues and challenges
- (2019) Claire Roddie et al. CYTOTHERAPY
- Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility
- (2019) Huaigeng Xu et al. Cell Stem Cell
- α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials
- (2019) Yingting Zhang et al. Frontiers in Immunology
- Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent Manner
- (2019) Simona Jahnke et al. Frontiers in Immunology
- NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma
- (2019) Xin Xu et al. CLINICAL CANCER RESEARCH
- Cell Biology of T Cell Receptor Expression and Regulation
- (2018) Andrés Alcover et al. Annual Review of Immunology
- The potential role of γδ T cells after allogeneic HCT for leukemia
- (2018) Rupert Handgretinger et al. BLOOD
- Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
- (2018) Anna Capsomidis et al. MOLECULAR THERAPY
- Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements
- (2018) Michael Kosicki et al. NATURE BIOTECHNOLOGY
- p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
- (2018) Robert J. Ihry et al. NATURE MEDICINE
- CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
- (2018) Emma Haapaniemi et al. NATURE MEDICINE
- IL-21 Selectively Protects CD62L+NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy
- (2018) Ho Ngai et al. JOURNAL OF IMMUNOLOGY
- Standardizing CAR-T therapy: Getting it scaled up
- (2018) Xiaofeng Dai et al. BIOTECHNOLOGY ADVANCES
- Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
- (2018) Antonia Rotolo et al. CANCER CELL
- Allogeneic CAR-T Cells: More than Ease of Access?
- (2018) Charlotte Graham et al. Cells
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
- (2017) Germán G Gornalusse et al. NATURE BIOTECHNOLOGY
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces hemogenic endothelium with lymphoid potential
- (2017) Yekaterina Galat et al. Stem Cell Research & Therapy
- CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
- (2016) Xiaojuan Liu et al. CELL RESEARCH
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals
- (2016) Z Chen et al. Mucosal Immunology
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- New Cell Sources for T Cell Engineering and Adoptive Immunotherapy
- (2015) Maria Themeli et al. Cell Stem Cell
- Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
- (2014) A. Heczey et al. BLOOD
- Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer
- (2014) Eva-Maria Surmann et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Direct induction of haematoendothelial programs in human pluripotent stem cells by transcriptional regulators
- (2014) Irina Elcheva et al. Nature Communications
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- T Lymphocyte Potential Marks the Emergence of Definitive Hematopoietic Progenitors in Human Pluripotent Stem Cell Differentiation Cultures
- (2012) Marion Kennedy et al. Cell Reports
- Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy
- (2011) S Merims et al. LEUKEMIA
- Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells
- (2010) M. Dusseaux et al. BLOOD
- The HLA genomic loci map: expression, interaction, diversity and disease
- (2009) Takashi Shiina et al. JOURNAL OF HUMAN GENETICS
- Generation of T Cells from Human Embryonic Stem Cell-Derived Hematopoietic Zones
- (2009) F. Timmermans et al. JOURNAL OF IMMUNOLOGY
- Interaction of KLRG1 with E-cadherin: New functional and structural insights
- (2008) Stephan Rosshart et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started